Opexa (Bilastine)

Bilastine selectively blocks peripheral H1 receptors on mast cells and blood vessels in the conjunctiva, preventing histamine‑mediated vasodilation, increased permeability, and nerve activation that cause allergic eye inflammation.

The prescribed dose of Opexa is determined by the treating clinician based on the patient’s age, severity of symptoms, and local prescribing guidelines. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for bilastine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Opexa.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Opexa (bilastine) offers a selective peripheral H1‑receptor blockade with a low propensity for sedation compared with some first‑generation antihistamines. Its efficacy in reducing ocular itching and redness is comparable to other second‑generation agents, while its safety profile is favorable for most patients.

Store Opexa at room temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Opexa is applied topically to the eye as directed by a healthcare professional. Typically, one or two drops are instilled into the affected eye(s) at the prescribed interval, avoiding contact with the tip of the bottle.

While rare, serious adverse events can include severe allergic reactions such as anaphylaxis, corneal edema, and sudden vision changes. Patients should seek immediate medical attention if they experience any of these symptoms.

Opexa should be avoided in individuals with known hypersensitivity to bilastine or any excipients in the formulation, and in patients where a major drug interaction (e.g., with ketoconazole or ritonavir) cannot be managed.